Actively Recruiting
International Multicenter Observational Study Collecting Data on Plasmablastic Lymphoma Patients
Led by Fondazione Italiana Linfomi - ETS · Updated on 2026-08-19
200
Participants Needed
23
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an international, multicenter, observational, and retrospective study focusing on patients diagnosed with plasmablastic lymphoma PBL. The study aims to gather detailed information on the clinical and pathological features, treatment approaches, outcomes, and prognostic factors such as clinical data, biomarkers, and radio-metabolic indicators in individuals affected by PBL. A centralized review of pathological samples is planned to assess diagnostic accuracy and to recommend an immunohistochemical panel for PBL diagnosis. Participants are patients diagnosed with PBL between January 1, 2000, and December 31, 2022, confirmed by histological analysis. The study will collect data from real-life diagnosis, staging, treatment regimens, and outcomes. Exploratory analyses will also be conducted to better understand PBL characteristics. This is an observational study without active treatment interventions. Participants medical records and histopathological materials will be reviewed and analyzed. The research team will evaluate outcomes such as overall survival at 36 months, disease staging, treatment response rates, progression-free survival, and other clinical factors. Data on chemotherapy regimens, involvement of specific organs, and frequencies of HIV and EBV at relapse will also be assessed. The study will continue until February 2028, with ongoing data collection and analysis.
CONDITIONS
Brief Title
Study on Plasmablastic Lymphoma Patients
Research Team
U
Uffici Studi FIL
U
Uffici Studi FIL
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here